Cellectar Biosciences vs Moleculin Biotech
CLRB and MBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLRB and MBRX compare
Cellectar Biosciences is the larger company, worth 1.3 times as much as Moleculin Biotech ($10.8M against $8.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLRB | MBRX |
|---|---|---|
| Size and price | ||
| Market cap | $10.8M | $8.2M |
| Share price | $1.14 | $7.87 |
| Change, 1 year | −67.4% | −96.8% |
| Change, 5 years | −99.5% | −100.0% |
| Beta (5Y) | 1.65 | 1.17 |
| Employees | 11 | 150K |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.5× (better) | 0.6× |
| Profitability | ||
| Return on equity | −170% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.44 (better) | 1.37 |
| Altman Z-score | −14.92 (better) | −19.51 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 36.8% | 0.89% |
| Held by insiders | 0.97% | – |
| Insider net buying, 12 months | $49.3K | – |
| Short interest, % of float | 2.3% | – |
Go deeper
- CLRB stock overview
- CLRB income statement
- CLRB valuation and score
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.